For the Inventor, By the Inventor

Enter inventor name

Glienicke, Germany

Wolfgang Schwede

USPTO Granted Patents = 41 (Patent Applications = 5)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 14 (Patent Applications = 17)

Average Co-Inventor Count = 6.2

ph-index = 8

Forward Citations = 232(Granted Patents)

Location History:

Berlin, DE (1995 - 2010)
Glienicke, DE (2008 - 2019)

Company Filing History:

17 out of 1,384

Schering Aktiengesellschaft

Bayer Intellectual Property Gmbh

Bayer Schering Pharma Ag

4. 5 out of 378

Bayer Pharma Aktiengesellschaft

Schering Akitengesellschaft

Years Active: 1995-2019

Loading Chart...

Loading Chart...

Loading Chart...

Areas of Expertise:

Benzimidazol-2-Amines

mIDH1 Inhibitors

Progesterone Receptor Antagonists

Pyrazolopyridines

Quinazoline Derivatives

Epothilone Derivatives

Steroid Esters

Nonsteroidal Progesterone Receptor Modulators

Antigestagenically Active Steroids

18 Norsteroids

3-Amino-Pyrazolo

Substituted Aminopyrazolopyridines

41 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10442772 - Benzimidazol-2-amines as mIDH1 inhibitors (2019-10-15),

2. 10172814 - Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof (2019-01-08),

3. 10155004 - 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases (2018-12-18),

4. 9957235 - Benzimidazol-2-amines as mIDH1 inhibitors (2018-05-01),

5. 9951027 - Benzimidazol-2-amines as MIDH1 inhibitors (2018-04-24),

6. 9717739 - 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases (2017-08-01),

7. 9206219 - 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, methods for the production thereof and the use thereof for treating diseases (2015-12-08),

8. 9156877 - 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzylidene derivatives, methods for the production thereof and use thereof for treating diseases (2015-10-13),

9. 9109004 - Progesterone receptor antagonists (2015-08-18),

10. 9102701 - 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-diene-11-ethynylphenyl derivatives, methods for the production thereof and use thereof for treating diseases (2015-08-11),

11. 9096640 - 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-diene-11-methylene oxyalkylene aryl derivatives, process for preparation thereof, and use thereof for treatment of diseases (2015-08-04),

12. 9096639 - 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylene phenyl derivatives, methods for the production thereof and use thereof for treating diseases (2015-08-04),

13. 9085603 - Progesterone receptor antagonists (2015-07-21),

14. 8278469 - 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases (2012-10-02),

15. 7977325 - 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents (2011-07-12),

Wolfgang Schwede: Innovator in Pharmaceutical Patents

Introduction

Wolfgang Schwede, based in Glienicke, Germany, is a prominent inventor with an impressive portfolio of 41 patents. His innovative work primarily focuses on pharmaceutical compounds, especially those targeting various diseases and medical conditions.

Latest Patents

Among his latest contributions to the field are two noteworthy patents. The first patent involves benzimidazol-2-amines as mIDH1 inhibitors. This invention relates to compounds designed for the treatment and prophylaxis of neoplasms, utilizing a specific general formula for their development. The methods of preparation and pharmaceutical applications of these compounds highlight their significance in modern medicine.

The second patent is centered around substituted pyridyl-cycloalkyl-carboxylic acids. These compounds aim to address multiple ailments, including pain syndromes, inflammatory-induced pains, and cancer-associated pain. The inventions emphasize their utility in manufacturing pharmaceutical compositions for both treatment and prevention of diseases in mammals.

Career Highlights

Wolfgang Schwede has made significant contributions throughout his career while working with reputable organizations. Notably, he has been associated with Schering Aktiengesellschaft and Bayer Intellectual Property GmbH. His work in these companies has allowed him to develop and refine his innovative ideas, leading to several impactful patents.

Collaborations

Throughout his career, Schwede has collaborated with esteemed colleagues, including Ulrich Klar and Andrea Rotgeri. These partnerships have fostered an environment of innovation and have led to advancements in pharmaceutical research and development.

Conclusion

In summary, Wolfgang Schwede's contributions to the field of pharmaceuticals through his extensive patent portfolio and collaborations with leading companies and professionals have established him as a significant inventor. His work continues to influence the landscape of modern medicine, particularly in the treatment of complex diseases.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…